Benazepril
Lotensin, Lotrel (benazepril) is a small molecule pharmaceutical. Benazepril was first approved as Lotensin on 1991-06-25. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Lotensin (generic drugs available since 2004-02-11)
CombinationsLotensin, Lotrel (generic drugs available since 2004-02-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amlodipine besylate
+
Benazepril hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOTREL | Novartis | N-020364 RX | 1995-03-03 | 6 products, RLD |
Benazepril hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOTENSIN | Validus Pharmaceuticals | N-019851 RX | 1991-06-25 | 3 products, RLD |
Show 1 discontinued
Benazepril hydrochloride
+
Hydrochlorothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOTENSIN HCT | Validus Pharmaceuticals | N-020033 RX | 1992-05-19 | 3 products, RLD |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amlodipine and benazepril hydrochloride | ANDA | 2023-06-20 |
| lotensin | New Drug Application | 2019-01-26 |
| lotrel | New Drug Application | 2022-03-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| diabetic nephropathies | EFO_0000401 | D003928 | — |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| left ventricular dysfunction | — | D018487 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 3 | 7 | — | 11 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | — | — | 2 | — | 2 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 1 | 1 | 2 |
| Dilated cardiomyopathy | D002311 | EFO_0000407 | I42.0 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary nephritis | D009394 | EFO_0004128 | Q87.81 | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | 1 | 1 | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | — | — | — | 2 | 11 | ||
| Fasting | D005215 | EFO_0002756 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BENAZEPRIL |
| INN | benazepril |
| Description | Benazepril is a benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and a prodrug. It is a benzazepine, a dicarboxylic acid monoester, an ethyl ester and a lactam. It is functionally related to a benazeprilat. It is a conjugate base of a benazepril(1+). |
| Classification | Small molecule |
| Drug class | antihypertensives (ACE inhibitors) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 86541-75-5 |
| RxCUI | 18867 |
| ChEMBL ID | CHEMBL838 |
| ChEBI ID | 3011 |
| PubChem CID | 5362124 |
| DrugBank | DB00542 |
| UNII ID | UDM7Q7QWP8 (ChemIDplus, GSRS) |
Target
Agency Approved
ACE
ACE
Organism
Homo sapiens
Gene name
ACE
Gene synonyms
DCP, DCP1
NCBI Gene ID
Protein name
angiotensin-converting enzyme
Protein synonyms
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, carboxycathepsin, CD143, CD143 antigen, dipeptidyl carboxypeptidase 1, Dipeptidyl carboxypeptidase I, Kininase II, peptidase P
Uniprot ID
Mouse ortholog
Ace (11421)
angiotensin-converting enzyme (P09470)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,792 documents
View more details
Safety
Black-box Warning
Black-box warning for: Amlodipine and benazepril hydrochloride, Lotensin, Lotrel
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more